Why Drug Names Don’t Translate

The same molecule goes by different names in different countries. Some of those names hide the fact that a drug is banned where you’re going.

A patient moves from Germany to the United States. They hand their prescription list to a new physician. On it: Novalgin 500mg, three times daily for pain.

The physician sees an unfamiliar brand name. If they look it up, they’ll find that Novalgin is metamizole (also called dipyrone) — an analgesic that the FDA withdrew from the US market in 1977 due to the risk of agranulocytosis, a potentially fatal reduction in white blood cells.

If they don’t look it up — because the word looks like a brand name they just don’t recognize — nothing flags the problem. The patient may continue taking a medication obtained from a family member abroad, or they may simply not mention it.

This is not a language problem. A perfect English translation of “Metamizol-Natrium (Novalgin) 500mg Tabletten” is “Metamizole sodium (Novalgin) 500mg tablets.” Both sentences are accurate. Neither tells a US physician that this drug is banned in their country.

The Brand Name Problem

Pharmaceutical companies register different brand names in different countries. The same molecule — the same chemical compound, manufactured to the same specifications — goes by names that bear no resemblance to each other.

Atorvastatin (the cholesterol-lowering statin):

US: Lipitor
Germany: Sortis
India: Atorva, Tonact, Lipikind
Brazil: Citalor
Turkey: Ator

A German prescription listing “Sortis 20mg” tells a US pharmacist nothing. It’s not that the pharmacist lacks German — it’s that “Sortis” is not a word in their professional vocabulary.

Paracetamol / Acetaminophen (the most common analgesic worldwide):

Most of the world: Paracetamol
US: Acetaminophen (Tylenol)
Germany: Paracetamol (ben-u-ron)
India: Paracetamol (Crocin, Dolo)
Thailand: Paracetamol (Sara, Tylenol)

The molecule is identical. The names create confusion — especially when a US physician sees “Paracetamol” and doesn’t immediately connect it to the acetaminophen their patient may already be taking, risking accidental double-dosing.

When “Legal” Changes at the Border

The harder problem than brand names is regulatory status. Drugs that are standard, over-the-counter medications in one country may be:

Banned in another (metamizole in the US)
Prescription-only where they were previously OTC
Controlled substances requiring special prescribing authority
Not approved (never submitted for regulatory review)

Metamizole: The Case Study

Metamizole (dipyrone) is one of the most prescribed analgesics in the world. It is available — often without a prescription — in Germany, Turkey, Brazil, Mexico, India, and much of Latin America and Asia.

It is banned in the United States, the United Kingdom, Japan, Sweden, and several other countries.

The risk: agranulocytosis, a sudden and severe drop in white blood cells that leaves the patient vulnerable to life-threatening infections. The incidence is rare (estimated 1 in 1,500 to 1 in 100,000 depending on the study), but the consequences are severe enough that several countries consider the risk unacceptable.

A patient who has taken Novalgin safely for years in Germany encounters no problem. That same patient, now in the US, holds a prescription for a drug that no US pharmacy can fill and no US physician can prescribe. They need to know this — and they need an alternative.

Google Translate renders the prescription in English. TranslateMed flags the ban, explains why, and suggests US alternatives that a physician can evaluate.

Codeine: Scheduling Differences

Codeine is another illustration. In many countries, low-dose codeine is available over the counter in combination products (codeine + paracetamol, codeine + ibuprofen). In the US, all codeine products are Schedule II-V controlled substances.

A patient arriving from the UK with a box of co-codamol (codeine + paracetamol, purchased OTC at Boots) is carrying a controlled substance in US legal terms. This matters for customs, for physician awareness, and for ongoing pain management.

Pseudoephedrine: OTC to Tracked

Pseudoephedrine (the decongestant in Sudafed) is freely available in most countries. In the US, it requires photo ID and signature under the Combat Methamphetamine Epidemic Act. In Mexico, it’s banned entirely. In Japan, it’s a controlled substance.

The same cold medication bought without a second thought in Germany may not be purchasable — or even legal to possess — in another country.

The LASA Problem Across Languages

Look-Alike, Sound-Alike (LASA) drugs are a recognized patient safety hazard within a single language. Across languages, the problem compounds.

Losartan (an angiotensin II receptor blocker, for hypertension) and Lisinopril (an ACE inhibitor, also for hypertension) are different drug classes with different mechanisms and contraindications. When drug names are transliterated phonetically between scripts — Cyrillic, Arabic, Thai, Japanese katakana — the phonetic similarity between names like Losartan and Lisinopril is amplified. Both begin with “L,” have similar syllable counts, and treat the same condition.

A handwritten prescription transliterated from Thai to English, or from Arabic to Latin script, may produce a name that looks more like the wrong drug than the right one.

Other documented LASA pairs that cause cross-border confusion:

Carvedilol (beta-blocker) vs. Carbamazepine (anticonvulsant) — look-alikes in handwriting across multiple scripts
Hydroxyzine (antihistamine) vs. Hydroxychloroquine (antimalarial/rheumatologic) — especially in handwritten records
Metformin (diabetes) vs. Metronidazole (antibiotic) — same prefix, widely prescribed, very different uses

The solution isn’t better handwriting. It’s verifying drug identity through INN and ATC code, not by name alone.

Dosage Conventions Vary by Country

The same drug, from the same manufacturer, may be prescribed at different standard doses in different countries — not because the drug is different, but because prescribing conventions evolved separately.

Japan is the clearest example. For several drug classes, standard Japanese doses run significantly lower than US or European equivalents:

Methotrexate for rheumatoid arthritis: US standard doses are often 15–25mg/week; Japanese guidelines have historically used 6–8mg/week.
Antipsychotics: Japanese prescribing patterns have conventionally used lower doses of agents like haloperidol than Western practice, in part due to pharmacogenomic differences in CYP2D6 metabolism common in East Asian populations.

When a patient’s record from Japan is read in the US, a dose that appears low by US standards is not an error — it reflects a different clinical convention. Without this context, a US physician may “correct” the dose upward, inadvertently increasing adverse event risk.

Dosage flagging in cross-border document translation isn’t about unit conversion. It’s about surfacing when a dose that looks wrong is actually right for a different healthcare system’s conventions.

Why General Translation Fails Here

The fundamental issue is that drug names are not linguistic entities. They are registry entries — pointers into national pharmaceutical databases maintained by regulatory agencies (FDA, BfArM, MHRA, CDSCO, Thai FDA).

Translating “Novalgin” to English doesn’t help, because “Novalgin” isn’t a German word — it’s a product registration in a German pharmaceutical database. The “translation” isn’t word-level. It’s a lookup: What molecule is this? What is that molecule’s regulatory status in the target country? What are the equivalent products there?

This lookup requires:

International Nonproprietary Names (INN) — the WHO-standardized generic names
ATC codes — the WHO Anatomical Therapeutic Chemical classification
National drug registries — what’s approved, what’s banned, what’s controlled
Brand name crosswalks — which brands correspond to which molecules in which countries

No general-purpose translator maintains this data. It’s not a translation task. It’s a pharmaceutical intelligence task.

The Safety Stakes

Drug name confusion in cross-border healthcare is not theoretical. Published case reports document:

Patients continuing banned medications obtained from family members abroad
Double-dosing when a physician doesn’t recognize that two brand names refer to the same molecule
Missed drug interactions when a foreign medication isn’t entered into the interaction-checking system because no one identified what it was
Controlled substance violations when patients carry OTC medications from home that are scheduled in the destination country

The common thread: the healthcare provider didn’t know what they didn’t know. The drug name was present in the chart. It just wasn’t interpretable in the local pharmaceutical context.

What Proper Drug Translation Looks Like

When TranslateMed encounters a drug name in a medical document, the output includes:

INN identification — the standardized generic name (e.g., Novalgin → metamizole)
ATC classification — the therapeutic class (e.g., N02BB02 — other pyrazolones)
Regulatory status in the target country — approved, banned, controlled, or not reviewed
Safety flags — critical alerts for banned or restricted medications
Equivalent products — local brand names for the same molecule, where available
Dosing context — any relevant dosing convention differences

This isn’t a better translation. It’s a different kind of output: pharmaceutical intelligence instead of linguistic conversion.

The Broader Pattern

Drug names are the most dramatic example of a pattern that runs through all medical document translation: the words translate, but the systems don’t.

ICD-10 diagnosis codes look the same across countries but carry different meanings. Dental procedure codes (GOZ, CDT, BEMA) have no cross-system equivalents without explicit mapping tables. Lab reference ranges use different units and different normal values.

In each case, a general-purpose translator produces output that looks complete — fluent, grammatically correct, apparently comprehensive — while leaving the hardest problems untouched.

The patient’s safety depends on someone noticing what’s missing. TranslateMed makes the missing parts visible.

TranslateMed flags banned and restricted medications across 47 countries. Try it free at translatemed.io.